Anti-tumor effects of pEgr-1-endostatin-TNF-α Recombinant plasmid expression induced by ionizing radiation

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 11, 2011, Pages 2933-2937

  Zhang, Yongchun ^a   Qiu, Wensheng ^a   Liang, Jun ^a   Yu, Zhuang ^a   Yue, Lu ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Endostatin; Gene radiotherapy; Irradiation; TNF

Indexed keywords

EID: 84863315617     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Herbst RS, Mullani NA, Davis DW (2002). Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol, 20, 3804-14.
2. Hsu H, Rainov NG, Quinones A, et al (2003). Combined radiation and cytochrome CYP4B1/4-ipomeanol gene therapy using the EGR1 promoter. Anticancer Res, 23, 2723-8.
3. Huang RP, Adamson ED (1995). A biological role for Egr-1 in cell survival following ultra-violet irradiation. Oncogene, 10, 467-75
4. Li L, Liu RY, Huang JL, et al (2006). Adenovirus-mediated intratumoral delivery of the human endostatin gene inhibits tumor growth in nasopharyngeal carcinoma. Int J Cancer, 118, 2064-71.
5. Liu LL, Smith MJ, Sun BS, et al (2009). Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model. Ann Surg Oncol, 16, 1403-11.
6. Mauceri HJ, Beckett MA, Liang H, et al (2009). Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy. Cancer Gene Ther, 16, 373-81.
7. Ponnazhagan S, Mahendra G, Kumar S, et al (2004). Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res, 64, 1781-7.
8. Senzer N, Mani S, Rosemurgy A, et al (2004). TNF erade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol, 22, 577-9.
9. Skovseth DK, VeugerMJ, Sorensen DR, et al (2005). Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivaseular cell recruitment in vivo. Blood, 105, 1044-51.
10. Tjin T, Sjin RM, Naspinski J, et al (2006). Endostatin therapy reveals a U - shaped curve for antitumor activity. Cancer Gene Ther, 13, 619-27.
11. Wang WD, Chen ZT, Li DZ, et al (2004). Oncostatin M gene therapy in mice bearing lung adenocarcinoma xenograft using a hypoxia/radiation dual-sensitive promoter. Zhonghua Jie He He Hu Xi Za Zhi, 27, 240-3.
12. Weichselbaum RR, Kufe DW, Hellman S, et al (2002). Radiation-induced tumor necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol, 3, 665-71.
13. Wu CM, Li XY (2004). Construction of pEgr-TNF alpha plasmid and experimental study on the effect of gene-radiotherapy on mouse melanoma. Chin J Oncol, 26, 143-5.